Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 7
- 主要终点
- global score of power-doppler activity measured by ultrasonography on 12 joints
研究概览
简要总结
To detect by sonography relapse of disease activity prior to clinical symptoms in RA patients treated by rituximab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •failure to at least one TNF-blocking agent
排除标准
- •pregnant or childbearing woman
- •Rituximab contraindication
- •woman unable to use contraceptive means
研究组 & 干预措施
rituximab
Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
干预措施: ESAOTE MyLab60 (Device)
rituximab
Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
干预措施: Rituximab (Drug)
结局指标
主要结局
global score of power-doppler activity measured by ultrasonography on 12 joints
时间窗: at 6 months after initiation of rituximab and then every 2 month over the follow-up period (18 months)
Each time point will be assessed since the main objective of the study is to detect the time of sonographic relapse prior to clinical relapse
次要结局
未报告次要终点
